The evolution of bladder preservation strategies has historically paralleled advances in systemic therapy for muscle-invasive bladder cancer (MIBC). Radiosensitizing agents incorporated into ...

Jason Efstathiou discusses the use of genomic classifiers and AI-based tools in personalizing radiation therapy for prostate cancer. Decipher®, a 22-gene expression classifier, assesses tumor biology ...

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a new developments in genitourinary radioligand therapy session and a presentation by Dr. Vadim Koshkin discussing an opportunity for ...

Hashim Hashim joins Diane Newman for a conversation on the definitions of lower urinary tract dysfunction and the role and timing of urodynamics in the diagnosis of the specific condition. They also ...

Association Between Baseline Prostate MRI PI-RADS Classification and Risk of Gleason Upgrade During Active Surveillance: A Systematic Review and Meta-Analysis - Beyond the Abstract ...

ESMO 2025 final results of PRESTO (AFT-19), phase III trial of combined androgen blockade in patients with high-risk, biochemically relapsed prostate cancer.

Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-Invasive Bladder Cancer (SURE-02): A Single-Arm, Phase 2 Study - Beyond the Abstract ...

2026 PSMA & Beyond: Advancing Radioligand Therapy: Toxicity, Trial Design, and Emerging TargetsSent on 29 March 2026 2026 PSMA & Beyond: Emerging Targets and Trial Insights in Prostate CancerSent on ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...

AUA 2025, Non–muscle-Invasive Bladder Cancer (NMIBC), SunRISe-5 Study, TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guérin, Recurrent ...

ASCO 2025 Phase 1/2 Duravelo-1 study, nectin-4–targeting zelenectide pevedotin (BT8009), pembrolizumab, cisplatin-ineligible patients, locally advanced or metastatic urothelial cancer.